共 39 条
- [1] [Anonymous], 2014, E SPEN J
- [4] Cohade C, 2003, J NUCL MED, V44, P170
- [6] Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial [J]. LANCET ONCOLOGY, 2014, 15 (13) : 1493 - 1502
- [9] DemarkWahnefried W, 1997, J AM DIET ASSOC, V97, P519, DOI 10.1016/S0002-8223(97)00133-8